Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
DelveInsight's PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...
The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial ...
Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion 1 ), in line with upgraded guidance of US$800-$820 million 2 (previously US$770-800 million). Q4 2025 ...
Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...
Blue Earth Therapeutics today announced that the first patients in the UK have been administered with the investigational ...
St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programmeThe patients received Lutetium (177Lu) rhPSMA-10.1 Injections at ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell carcinoma (RCC) who maintained a BMI of 35 or higher after diagnosis had improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback